Results 161 to 170 of about 10,523 (190)
Some of the next articles are maybe not open access.
Current Opinion in Lipidology, 2013
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire +2 more sources
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire +2 more sources
PCSK9 inhibitors and cardiovascular outcomes
Expert Opinion on Biological Therapy, 2019Introduction: Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering drugs are beneficial for the primary and secondary prevention of cardiovascular (CV) disease.
Daniel, Steffens +6 more
openaire +2 more sources
Lipid lowering with PCSK9 inhibitors
Nature Reviews Cardiology, 2014Statins are the most-effective therapy currently available for lowering the LDL-cholesterol (LDL-C) level and preventing cardiovascular events. Additional therapies are necessary for patients who cannot reach the target LDL-C level when taking the maximum-tolerated dose of a statin.
Razvan T, Dadu, Christie M, Ballantyne
openaire +2 more sources
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Current Cardiology Reports, 2013Despite the efficacy of statin therapy, patients treated with these agents face substantial residual risk that is associated with achieved levels of LDL cholesterol (LDL-C). These observations suggest a potential benefit of additional strategies to promote further LDL-C reduction.
Rose Q, Do +2 more
openaire +2 more sources
Expanded Indication for PCSK9 Inhibitors
The Medical Letter on Drugs and TherapeuticsThe FDA has approved changes to the wording of the cardiovascular risk reduction indications for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab (Repatha) and alirocumab (Praluent). Both drugs are now approved to reduce the risk of major adverse cardiovascular events (MACE) in adults at increased risk for these events ...
openaire +2 more sources
The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia
Annals of Pharmacotherapy, 2018To evaluate the efficacy, safety, and cost-effectiveness of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and describe its place in therapy for the treatment of hypercholesterolemia.A search of MEDLINE, CINAHL, and Clinicaltrials.gov was performed from January 2012 to March 2018 to identify literature pertaining to PCSK9 inhibitors ...
Roshni S. Patel +2 more
openaire +2 more sources
Third generation PCSK9-inhibitors
European Heart Journal, 2023Ulrich Laufs +2 more
openaire +3 more sources
PCSK9 inhibitors: clinical evidence and implementation
Nature Reviews Cardiology, 2018The gene encoding PCSK9 was first identified and linked to the phenotype of familial hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role of PCSK9 in the regulation of LDL-receptor recycling and identified loss-of-function variants of PCSK9 that were associated with low circulating levels of LDL cholesterol (LDL-C ...
openaire +2 more sources
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
Expert Opinion on Investigational Drugs, 2023John R Burnett, Amanda J Hooper
exaly